FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1917632054> ?p ?o ?g. }

• W1917632054 endingPage "158" @default.
• W1917632054 startingPage "158" @default.
• W1917632054 abstract "To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall survival, progression-free survival (PFS), objective response, and safety, and to assess health-related quality of life (QOL) and pharmacokinetics of both drugs and their metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboximide (MTIC).Patients were randomized to receive either oral temozolomide at a starting dosage of 200 mg/m(2)/d for 5 days every 28 days or intravenous (IV) DTIC at a starting dosage of 250 mg/m(2)/d for 5 days every 21 days.In the intent-to-treat population, median survival time was 7.7 months for patients treated with temozolomide and 6.4 months for those treated with DTIC (hazards ratio, 1.18; 95% confidence interval [CI], 0.92 to 1.52). Median PFS time was significantly longer in the temozolomide-treated group (1.9 months) than in the DTIC-treated group (1.5 months) (P =.012; hazards ratio, 1.37; 95% CI, 1.07 to 1.75). No major difference in drug safety was observed. Temozolomide was well tolerated and produced a noncumulative, transient myelosuppression late in the 28-day cycle. The most common nonhematologic toxicities were mild to moderate nausea and vomiting, which were easily managed. Temozolomide therapy improved health-related QOL; more patients showed improvement or maintenance of physical functioning at week 12. Systemic exposure (area under the curve) to the parent drug and the active metabolite, MTIC, was higher after treatment with oral temozolomide than after IV administration of DTIC.Temozolomide demonstrates efficacy equal to that of DTIC and is an oral alternative for patients with advanced metastatic melanoma." @default.
• W1917632054 created "2016-06-24" @default.
• W1917632054 creator A5002108213 @default.
• W1917632054 creator A5002644565 @default.
• W1917632054 creator A5005738281 @default.
• W1917632054 creator A5011257308 @default.
• W1917632054 creator A5025919899 @default.
• W1917632054 creator A5031113622 @default.
• W1917632054 creator A5031661938 @default.
• W1917632054 creator A5034365278 @default.
• W1917632054 creator A5041507222 @default.
• W1917632054 creator A5041627641 @default.
• W1917632054 creator A5051430596 @default.
• W1917632054 creator A5060360003 @default.
• W1917632054 creator A5063009340 @default.
• W1917632054 creator A5063293745 @default.
• W1917632054 creator A5071545176 @default.
• W1917632054 creator A5085631923 @default.
• W1917632054 creator A5086103989 @default.
• W1917632054 creator A5086174841 @default.
• W1917632054 creator A5087782965 @default.
• W1917632054 date "2000-01-01" @default.
• W1917632054 modified "2023-10-14" @default.
• W1917632054 title "Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma" @default.
• W1917632054 cites W1525505117 @default.
• W1917632054 cites W1835101589 @default.
• W1917632054 cites W1966682923 @default.
• W1917632054 cites W1973027090 @default.
• W1917632054 cites W1980195588 @default.
• W1917632054 cites W1993808515 @default.
• W1917632054 cites W2025101604 @default.
• W1917632054 cites W2039403483 @default.
• W1917632054 cites W2040432387 @default.
• W1917632054 cites W2079786467 @default.
• W1917632054 cites W2109549713 @default.
• W1917632054 cites W2164569272 @default.
• W1917632054 cites W2167571044 @default.
• W1917632054 cites W2308844187 @default.
• W1917632054 cites W235444781 @default.
• W1917632054 cites W4249905861 @default.
• W1917632054 doi "https://doi.org/10.1200/jco.2000.18.1.158" @default.
• W1917632054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10623706" @default.
• W1917632054 hasPublicationYear "2000" @default.
• W1917632054 type Work @default.
• W1917632054 sameAs 1917632054 @default.
• W1917632054 citedByCount "1114" @default.
• W1917632054 countsByYear W19176320542012 @default.
• W1917632054 countsByYear W19176320542013 @default.
• W1917632054 countsByYear W19176320542014 @default.
• W1917632054 countsByYear W19176320542015 @default.
• W1917632054 countsByYear W19176320542016 @default.
• W1917632054 countsByYear W19176320542017 @default.
• W1917632054 countsByYear W19176320542018 @default.
• W1917632054 countsByYear W19176320542019 @default.
• W1917632054 countsByYear W19176320542020 @default.
• W1917632054 countsByYear W19176320542021 @default.
• W1917632054 countsByYear W19176320542022 @default.
• W1917632054 countsByYear W19176320542023 @default.
• W1917632054 crossrefType "journal-article" @default.
• W1917632054 hasAuthorship W1917632054A5002108213 @default.
• W1917632054 hasAuthorship W1917632054A5002644565 @default.
• W1917632054 hasAuthorship W1917632054A5005738281 @default.
• W1917632054 hasAuthorship W1917632054A5011257308 @default.
• W1917632054 hasAuthorship W1917632054A5025919899 @default.
• W1917632054 hasAuthorship W1917632054A5031113622 @default.
• W1917632054 hasAuthorship W1917632054A5031661938 @default.
• W1917632054 hasAuthorship W1917632054A5034365278 @default.
• W1917632054 hasAuthorship W1917632054A5041507222 @default.
• W1917632054 hasAuthorship W1917632054A5041627641 @default.
• W1917632054 hasAuthorship W1917632054A5051430596 @default.
• W1917632054 hasAuthorship W1917632054A5060360003 @default.
• W1917632054 hasAuthorship W1917632054A5063009340 @default.
• W1917632054 hasAuthorship W1917632054A5063293745 @default.
• W1917632054 hasAuthorship W1917632054A5071545176 @default.
• W1917632054 hasAuthorship W1917632054A5085631923 @default.
• W1917632054 hasAuthorship W1917632054A5086103989 @default.
• W1917632054 hasAuthorship W1917632054A5086174841 @default.
• W1917632054 hasAuthorship W1917632054A5087782965 @default.
• W1917632054 hasConcept C126322002 @default.
• W1917632054 hasConcept C141071460 @default.
• W1917632054 hasConcept C143998085 @default.
• W1917632054 hasConcept C2776694085 @default.
• W1917632054 hasConcept C2777389519 @default.
• W1917632054 hasConcept C2780580376 @default.
• W1917632054 hasConcept C2780852908 @default.
• W1917632054 hasConcept C2780964509 @default.
• W1917632054 hasConcept C2908647359 @default.
• W1917632054 hasConcept C31760486 @default.
• W1917632054 hasConcept C71924100 @default.
• W1917632054 hasConcept C99454951 @default.
• W1917632054 hasConceptScore W1917632054C126322002 @default.
• W1917632054 hasConceptScore W1917632054C141071460 @default.
• W1917632054 hasConceptScore W1917632054C143998085 @default.
• W1917632054 hasConceptScore W1917632054C2776694085 @default.
• W1917632054 hasConceptScore W1917632054C2777389519 @default.
• W1917632054 hasConceptScore W1917632054C2780580376 @default.
• W1917632054 hasConceptScore W1917632054C2780852908 @default.
• W1917632054 hasConceptScore W1917632054C2780964509 @default.

• next